CY1117209T1 - Συνθεσεις περιλαμβανοντας 15-ηερε και μεθοδοι χρησης των ιδιων - Google Patents
Συνθεσεις περιλαμβανοντας 15-ηερε και μεθοδοι χρησης των ιδιωνInfo
- Publication number
- CY1117209T1 CY1117209T1 CY20161100155T CY161100155T CY1117209T1 CY 1117209 T1 CY1117209 T1 CY 1117209T1 CY 20161100155 T CY20161100155 T CY 20161100155T CY 161100155 T CY161100155 T CY 161100155T CY 1117209 T1 CY1117209 T1 CY 1117209T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- owners
- days
- compositions including
- fatty liver
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1301626.6A GB201301626D0 (en) | 2013-01-30 | 2013-01-30 | Composition comprising 15-OHEPA and methods of using the same |
| EP13176516.6A EP2762143B1 (en) | 2013-01-30 | 2013-07-15 | Compositions comprising 15-HEPE and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1117209T1 true CY1117209T1 (el) | 2017-04-05 |
Family
ID=47891001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100155T CY1117209T1 (el) | 2013-01-30 | 2016-02-25 | Συνθεσεις περιλαμβανοντας 15-ηερε και μεθοδοι χρησης των ιδιων |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US20150224076A1 (enExample) |
| EP (2) | EP2762143B1 (enExample) |
| JP (2) | JP6363104B2 (enExample) |
| KR (6) | KR20250105691A (enExample) |
| CN (2) | CN105120872B (enExample) |
| AU (2) | AU2014211628B2 (enExample) |
| BR (1) | BR112015018270A2 (enExample) |
| CA (1) | CA2897343C (enExample) |
| CY (1) | CY1117209T1 (enExample) |
| DK (1) | DK2762143T3 (enExample) |
| ES (2) | ES2564025T3 (enExample) |
| GB (1) | GB201301626D0 (enExample) |
| HR (1) | HRP20160203T1 (enExample) |
| HU (1) | HUE026901T2 (enExample) |
| IL (3) | IL239893A (enExample) |
| MX (2) | MX364646B (enExample) |
| NZ (1) | NZ709803A (enExample) |
| PH (1) | PH12015501582B1 (enExample) |
| PL (1) | PL2762143T3 (enExample) |
| PT (1) | PT2762143E (enExample) |
| RS (1) | RS54584B1 (enExample) |
| RU (2) | RU2671208C2 (enExample) |
| SG (2) | SG10201806854XA (enExample) |
| SI (1) | SI2762143T1 (enExample) |
| SM (1) | SMT201600069B (enExample) |
| WO (1) | WO2014118097A1 (enExample) |
| ZA (2) | ZA201505018B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| US10017453B2 (en) | 2013-11-15 | 2018-07-10 | Ds Biopharma Limited | Pharmaceutically acceptable salts of fatty acids |
| AU2015204531B2 (en) * | 2014-01-10 | 2019-11-14 | Afimmune Limited | Pharmaceutical compositions comprising 15-HEPE and methods of treating asthma and lung disorders using same |
| MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| HK1247136A1 (zh) * | 2015-01-16 | 2018-09-21 | Afimmune Limited | 包含15-hepe的组合物和其使用方法 |
| US20180104201A1 (en) | 2015-04-28 | 2018-04-19 | Pronova Biopharma Norge As | Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic steatohepatitis |
| CN117402059A (zh) * | 2015-05-13 | 2024-01-16 | Ds生物制药有限公司 | 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法 |
| US20170020836A1 (en) * | 2015-07-21 | 2017-01-26 | Dignity Sciences Limited | Compositions Comprising 15-HEPE and Methods of Treating or Preventing Cancer and Neurologic Disease |
| KR20220038818A (ko) * | 2015-12-18 | 2022-03-29 | 애피뮨 리미티드 | 15-hepe를 포함하는 조성물 및 이를 사용하는 방법 |
| PT3720431T (pt) | 2017-12-06 | 2024-12-05 | Basf As | Derivados de ácidos gordos para o tratamento da esteato-hepatite não alcoólica |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| CN115215725A (zh) * | 2021-04-15 | 2022-10-21 | 宋晓瑜 | 一种制备乙酸薰衣草酯及薰衣草醇的方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05186342A (ja) * | 1992-01-10 | 1993-07-27 | Fujirebio Inc | 免疫調節作用を併せもつ抗炎症剤 |
| AU673700B2 (en) | 1993-01-27 | 1996-11-21 | Scotia Holdings Plc | Triglycerides |
| EP0671901B1 (en) | 1993-10-01 | 1998-01-14 | R.P. Scherer Corporation | Compositions for dispensing fragrances |
| US20020055539A1 (en) * | 1996-10-02 | 2002-05-09 | Bockow Barry I. | Compositions and methods for treating cardiovascular conditions |
| AU7240398A (en) * | 1998-05-08 | 1999-11-29 | Rolf Berge | Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions |
| JP2000191525A (ja) | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
| EP1762557B1 (en) | 2000-02-16 | 2011-04-06 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
| US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
| NZ529339A (en) | 2001-05-30 | 2004-08-27 | Laxdale Ltd | Coenzyme Q and eicosapentaenoic acid (EPA) |
| CN1250230C (zh) * | 2001-09-30 | 2006-04-12 | 中国药品生物制品检定所 | 海狗油作为制备治脂肪肝药的应用 |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| JP2005179211A (ja) | 2003-12-17 | 2005-07-07 | Idemitsu Kosan Co Ltd | 皮膚外用剤組成物 |
| EP1711173A2 (en) | 2003-12-31 | 2006-10-18 | Igennus Limited | Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof |
| US20050239889A1 (en) | 2004-04-26 | 2005-10-27 | Jean Gosselin | In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration |
| US20050282781A1 (en) | 2004-06-18 | 2005-12-22 | Shibnath Ghosal | Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids |
| CN101043884A (zh) | 2004-07-01 | 2007-09-26 | 谢彭斯眼科研究公司 | 用于治疗眼部疾病和病症的组合物和方法 |
| WO2007081773A2 (en) * | 2006-01-05 | 2007-07-19 | Reliant Pharmaceuticals, Inc | Treatment of fatty liver |
| EP3285072B1 (en) | 2006-08-08 | 2020-04-15 | Metabolon, Inc. | Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof |
| US20100120914A1 (en) * | 2007-03-30 | 2010-05-13 | Kowa Company, Ltd. | Medicament for prophylactic and/or therapeutic treatment of hepatic steatosis or non-alcoholic steatohepatitis |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| WO2009154230A1 (ja) * | 2008-06-17 | 2009-12-23 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| EP2415748A4 (en) * | 2009-02-20 | 2013-08-07 | Univ Tokyo | NEW INFLAMMATORY COMPOUNDS |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| CA2690488C (en) | 2010-01-19 | 2013-06-11 | Accucaps Industries Limited | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
| EP2607358A4 (en) * | 2010-08-19 | 2014-01-29 | Univ Tokyo | NEW OMEGA-3 FATTY ACIDS RECOVERY-RESISTANT METABOLITE |
| US20130310422A1 (en) | 2010-09-01 | 2013-11-21 | The General Hospital Corporation | Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine |
| WO2012135032A2 (en) | 2011-03-25 | 2012-10-04 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory particles |
| US20120264824A1 (en) | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| US8936803B2 (en) | 2011-10-19 | 2015-01-20 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| KR20140113921A (ko) | 2011-11-29 | 2014-09-25 | 디그너티 사이언스 리미티드 | 20-탄소 지방산을 포함하는 조성물 및 이를 제조 및 사용하는 방법 |
| CN107050457A (zh) | 2012-01-06 | 2017-08-18 | 翁特拉制药公司 | 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物 |
| US20120264705A1 (en) * | 2012-01-26 | 2012-10-18 | Dignity Sciences Limited | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| US20130267598A1 (en) | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| JP6370775B2 (ja) | 2012-05-10 | 2018-08-08 | ソルテックス エヌエー エルエルシー | 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油 |
| GB201213484D0 (en) * | 2012-07-30 | 2012-09-12 | Dignity Sciences Ltd | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same |
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| US20170020836A1 (en) * | 2015-07-21 | 2017-01-26 | Dignity Sciences Limited | Compositions Comprising 15-HEPE and Methods of Treating or Preventing Cancer and Neurologic Disease |
| KR20220038818A (ko) | 2015-12-18 | 2022-03-29 | 애피뮨 리미티드 | 15-hepe를 포함하는 조성물 및 이를 사용하는 방법 |
-
2013
- 2013-01-30 GB GBGB1301626.6A patent/GB201301626D0/en not_active Ceased
- 2013-07-15 ES ES13176516.6T patent/ES2564025T3/es active Active
- 2013-07-15 ES ES15197389T patent/ES2759448T3/es active Active
- 2013-07-15 PL PL13176516T patent/PL2762143T3/pl unknown
- 2013-07-15 EP EP13176516.6A patent/EP2762143B1/en active Active
- 2013-07-15 DK DK13176516.6T patent/DK2762143T3/en active
- 2013-07-15 EP EP15197389.8A patent/EP3058943B1/en active Active
- 2013-07-15 HU HUE13176516A patent/HUE026901T2/en unknown
- 2013-07-15 PT PT131765166T patent/PT2762143E/pt unknown
- 2013-07-15 SI SI201330140T patent/SI2762143T1/sl unknown
- 2013-07-15 RS RS20160118A patent/RS54584B1/sr unknown
-
2014
- 2014-01-24 KR KR1020257022099A patent/KR20250105691A/ko active Pending
- 2014-01-24 BR BR112015018270A patent/BR112015018270A2/pt not_active Application Discontinuation
- 2014-01-24 RU RU2015136849A patent/RU2671208C2/ru active
- 2014-01-24 SG SG10201806854XA patent/SG10201806854XA/en unknown
- 2014-01-24 AU AU2014211628A patent/AU2014211628B2/en not_active Ceased
- 2014-01-24 KR KR1020247001131A patent/KR20240011872A/ko not_active Ceased
- 2014-01-24 KR KR1020157020952A patent/KR102274963B1/ko active Active
- 2014-01-24 KR KR1020237009963A patent/KR20230047201A/ko not_active Ceased
- 2014-01-24 JP JP2015555661A patent/JP6363104B2/ja not_active Expired - Fee Related
- 2014-01-24 KR KR1020227028323A patent/KR102514913B1/ko active Active
- 2014-01-24 CN CN201480006443.XA patent/CN105120872B/zh active Active
- 2014-01-24 CA CA2897343A patent/CA2897343C/en active Active
- 2014-01-24 KR KR1020217020740A patent/KR102434817B1/ko active Active
- 2014-01-24 WO PCT/EP2014/051455 patent/WO2014118097A1/en not_active Ceased
- 2014-01-24 CN CN201911258822.9A patent/CN111214464A/zh active Pending
- 2014-01-24 MX MX2015009803A patent/MX364646B/es active IP Right Grant
- 2014-01-24 SG SG11201505457PA patent/SG11201505457PA/en unknown
- 2014-01-24 RU RU2018136872A patent/RU2018136872A/ru not_active Application Discontinuation
- 2014-01-24 NZ NZ709803A patent/NZ709803A/en not_active IP Right Cessation
-
2015
- 2015-04-24 US US14/695,865 patent/US20150224076A1/en not_active Abandoned
- 2015-07-12 IL IL239893A patent/IL239893A/en active IP Right Grant
- 2015-07-13 ZA ZA2015/05018A patent/ZA201505018B/en unknown
- 2015-07-16 PH PH12015501582A patent/PH12015501582B1/en unknown
- 2015-07-29 MX MX2019005082A patent/MX2019005082A/es unknown
-
2016
- 2016-02-25 CY CY20161100155T patent/CY1117209T1/el unknown
- 2016-02-26 HR HRP20160203T patent/HRP20160203T1/hr unknown
- 2016-03-08 SM SM201600069T patent/SMT201600069B/xx unknown
- 2016-07-21 ZA ZA2016/05125A patent/ZA201605125B/en unknown
-
2017
- 2017-04-06 IL IL251639A patent/IL251639A0/en active IP Right Grant
-
2018
- 2018-06-27 JP JP2018121494A patent/JP2018172409A/ja active Pending
- 2018-07-16 AU AU2018206685A patent/AU2018206685A1/en not_active Abandoned
-
2019
- 2019-04-07 IL IL265876A patent/IL265876A/en unknown
- 2019-07-31 US US16/527,841 patent/US10813903B2/en active Active
-
2020
- 2020-09-16 US US17/022,180 patent/US20210228524A1/en not_active Abandoned
-
2021
- 2021-04-16 US US17/232,862 patent/US20210244697A1/en not_active Abandoned
-
2022
- 2022-03-23 US US17/702,294 patent/US20220347147A1/en not_active Abandoned
-
2023
- 2023-12-06 US US18/531,259 patent/US20250186384A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125977T1 (el) | Ενωσεiς που αλληλεπιδρουν με τη γλυκανη και μεθοδοι χρησης | |
| MX2019005082A (es) | Composiciones que comprenden 15-ohepa y metodos para usar las mismas. | |
| CY1121517T1 (el) | Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib | |
| CY1123845T1 (el) | Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX387817B (es) | Uso de acidos grasos de cadena corta en prevencion de cancer. | |
| PH12017501956A1 (en) | Compositions of obeticholic acid and methods of use | |
| WO2014197871A3 (en) | Antibody-drug conjugates, compositions and methods of use | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| MX2017001279A (es) | Usos y composiciones de la flagelina. | |
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| EA201691940A1 (ru) | Новые соединения | |
| EA201591004A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| JO3155B1 (ar) | معدِّل نكهة حلوة | |
| CY1122441T1 (el) | Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους | |
| MY186547A (en) | 4?-fluoro-2?-methyl substituted nucleoside derivatives | |
| CY1121326T1 (el) | Υποκατεστημενη 2,4 διαμινο-κινολινη ως νεοι αντικαρκινικοι παραγοντες | |
| CY1120759T1 (el) | Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης | |
| PL423259A1 (pl) | Koniugaty przeciwciało-ureaza dla celów terapeutycznych | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| MY182134A (en) | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and uses thereof | |
| BR112015023383A2 (pt) | compostocomposição farmacêutica; e método de modulação | |
| EA201591704A1 (ru) | Новые устойчивые соли пентадекапептида, способ их получения, их применение в производстве фармацевтических составов и их применение в терапии | |
| MX2019002579A (es) | Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado. | |
| PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs |